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Abstract
Objective—To examine the long-term outcomes of community-based elderly African Americans
by following their transitions from normal cognition to mild cognitive impairment (MCI), and to
dementia.
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Methods—Participants were from the community-based Indianapolis Dementia Project. A total
of 4104 African Americans were enrolled in 1992 or 2001 and followed until 2009 with regularly
scheduled evaluation of cognitive assessment. A two-stage sampling was used at each evaluation
to select individuals for extensive clinical assessment following the results of stage one cognitive
testing. Age and gender specific incidence, progression and reversion rates for MCI were derived
using the person-year method in a dynamic cohort and predicted probabilities from weighted
multinomial logistic models of transitional probabilities among normal cognition, MCI and
dementia.
Results—Annual overall incidence rate for MCI is 5.6% (95% CI: 4.6–6.6%). Annual
progression rate from MCI to dementia is 5.9% (95% CI: 5.3–6.5%) and annual reversion rate
from MCI to normal is 18.6% (95% CI: 16.7–20.4%). Both MCI incidence rates and MCI to
dementia progression rates increase with age, while reversion rates from MCI to normal decrease
with age.
Conclusion—MCI progression to dementia is much more frequent in the older age groups than
in the younger participants where reversion to normal cognition is more common. Future research
is needed to determine factors related to the heterogeneous outcomes in MCI individuals.
Keywords
mild cognitive impairment; dementia; African Americans
Introduction
Dementia including Alzheimer’s disease (AD) affects millions of elderly Americans and is
emerging as a major public health problem. In an effort to identify individuals at higher risk
for dementia, the intermediate stage between normal cognition and dementia has been
characterized as mild cognitive impairment (MCI).1 Individuals in the MCI group were
shown to progress to dementia at a higher rate than those with normal cognition suggesting
that some MCI individuals may be at the early stage of dementia. However, epidemiological
studies have also found that a substantial proportion of individuals with MCI revert to
normal cognition indicating a highly heterogeneous nature of the MCI group.2–7 Information
on the epidemiology of individuals with MCI including incidence, progression and reversion
can help identify individuals at risk for dementia and lead to potential preventive measures
in delaying conversion to dementia.
Previous studies on MCI have focused on separate cohorts of cognitive normal individuals at
baseline for estimating incidence and cohorts of individuals with MCI at baseline for
dementia progression. These studies have reported annual MCI incidence rates ranging from
0.85% to 12.2%3–5, 7–19 and annual progression rates to dementia ranging from 0.9% to
15.3%.20 Since MCI is known to be a transient state between cognitive normal and
dementia, it is essential to examine the incidence and progression of MCI simultaneously in
population-based cohorts to appropriately account for transitions between normal cognition
and MCI during follow-up. Few studies, if any, have examined the long-term outcomes of
community-based elderly individuals by following their transitions from normal cognition to
MCI and dementia. Various studies have indicated that African Americans were more likely
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than whites to have AD and other dementia.21 African Americans are also known to have
higher prevalence of hypertension and diabetes than other ethnic groups, leading to
potentially higher rates of MCI or MCI conversion rates.22–23 However, there has been little
research on the natural history of MCI in African Americans. In this study, we report the
incidence, progression and reversion rates of MCI in an elderly African American cohort
from the Indianapolis Dementia Project.
Methods
Study Participants
Participants were from the Indianapolis cohort of the Indianapolis-Ibadan Dementia Project,
a longitudinal study examining risk factors for dementia. Recruitment to the study was
conducted at two time points. In the first recruitment in 1992, a cohort of African Americans
age 65 or older living in Indianapolis were enrolled in the study. The geographic target area
used in the study consisted of 29 contiguous census tracts in which African Americans
represented 80% of the population in the 1990 U.S. census. Interviewers went door-to-door
to randomly sampled addresses to invite African Americans age 65 years and over to
participate. In 1992, 2,212 individuals were enrolled while 249 (9.6%) refused, and 121
(4.7%) were too sick to participate.
In 2001, the project enrolled additional community-dwelling subjects randomly selected
from Medicare records, who were self- identified as African-Americans, and were at least 70
years of age. The age cut-off for the 2001 cohort was chosen in order to maintain
comparability with the 1992 cohort since the youngest participants in the 1992 cohort had
since turned 70. Out of 7,583 eligible individuals, interviewers were able to contact 4,433 by
telephone or home visit. Of those contacted, 1,892 (43%) were enrolled, 2,020 (46%)
refused, 369 (8%) were too ill, 100 (2%) were deceased, 54 (1%) had moved to a nursing
home, and 14 (0.3%) were not African American. The two cohorts were similar in basic
demographics. Mean age during the 2001 evaluation was 77.4 (SD=6.0) for the 1992 cohort
and 76.8 (SD=5.6) for the 2001 cohort. The two cohorts also have similar gender
distributions (65.3% female in the 1992 cohort and 65.0% in the 2001 cohort).24 All
participants agreed to undergo regular follow-up cognitive assessment and clinical
evaluations. The study was approved by the Indiana University-Purdue University of
Indianapolis Institutional Review Board. All subjects enrolled provided informed consent.
Details on the assembling of the original cohort and the enrichment cohort were described
elsewhere.24–25
Study Design
The Indianapolis-Ibadan Dementia Project is a prospective community based study with a
baseline evaluation followed by regular evaluations scheduled two to three years apart.
Participants in the 1992 cohort were evaluated for up to 7 times, at 1992, 1995, 1998, 2001,
2004, 2007 and 2009. Participants in the 2001 cohort were evaluated for up to 4 times, at
2001, 2004, 2007 and 2009.
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A two-stage design was used at each evaluation with in-home cognitive and functional
evaluations for all participants followed by a full diagnostic workup of selected participants
based on the performance of stage one cognitive tests. After each stage one evaluation, study
participants were divided into three performance groups (good, intermediate and poor) based
on their cognitive and functional scores obtained during the in-home assessment and
changes in scores from previous evaluations.26 Percentages sampled from each performance
category were chosen to ensure that participants with the highest probability of dementia
would be clinically assessed. All participants in the poor performance group were invited to
be clinically assessed. Participants were randomly sampled from the intermediate
performance group until 50% had clinical assessments and from the good performance
group until 5% had clinical assessments.
Each clinically assessed participant received a diagnosis of “normal”, MCI, or dementia,
with further subtypes for those diagnosed with dementia (see section on Clinical Evaluation
below). All individuals diagnosed as demented reached their endpoint in the study and were
no longer followed. Participants who were diagnosed as MCI in a previous wave proceeded
directly to the clinical assessment stage regardless of their first stage scores.
Cognitive Instruments
The Community Screening Interview for Dementia (CSID) was used during the first stage
in-home assessment with a cognitive assessment of the study participant and an interview
with a close relative evaluating the daily functioning of the participant. The CSID was
developed by our group specifically for use in comparative epidemiological studies of
dementia in culturally disparate populations.27–28 The cognitive assessment in CSID
evaluates multiple cognitive domains (language, attention and calculation, memory,
orientation, praxis, and comprehension and motor response) and details of its content and
development are described elsewhere.12–14
Clinical Evaluation
Clinical evaluations included (1) a neuropsychological battery adapted from the Consortium
to Establish a Registry of Alzheimer’s Disease (CERAD);29 (2) a standardized neurologic
and physical exam, and functional status review (The Clinician Home-based Interview to
assess Function CHIF);30 and (3) a structured interview with a close relative adapted from
the Cambridge Examination for Mental Disorders of the Elderly informant interview
(CAMDEX).31–32 Following the second stage of evaluation, participants were diagnosed as
having normal cognitive function, dementia, or MCI. Diagnosis was made in a consensus
diagnostic conference of clinicians reviewing the CERAD neuropsychological test battery,
the physician’s assessment, the informant interview, and available medical records.
Dementia was diagnosed with both the Diagnostic and Statistical Manual of Mental
Disorders, Revised Third Edition (DSM-III-R)33 and International Classification of
Diseases, 10th Revision (ICD-10)34 criteria. AD was diagnosed using criteria proposed by
NINCDS/ADRDA. 35 Criteria for MCI were as follows: informant–reported decline in
cognition, clinician’s detected impairment in cognition during the assessment, or cognitive
test scores 1.5 SD below the mean of the normative reference sample and normal
instrumental and basic activities of daily living (based on the informant interview).7, 17, 36–37
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Other Information
Demographic information including age, sex and education were available on all study
participants. Information was also collected on alcohol and smoking history on whether the
participant ever consumed alcohol or smoked regularly. In addition, medical conditions that
may affect cognitive function were collected at each of the evaluation times. In particular,
medical history of coronary heart disease (CHD), cancer, diabetes, heart attack,
hypertension, Parkinson’s disease, stroke and depression was collected from self or
informant reports as affirmative answers to whether the participants had ever been
diagnosed or treated for these diseases.
Statistical Analyses
Comparisons of baseline demographic characteristics and medical history among
participants with incident dementia, those with MCI at any given time during the study and
participants who were not diagnosed as demented or MCI were conducted using Chi-square
tests for categorical variables and analysis of variance for continuous variables for the 1992
cohort and the 2001 cohort separately.
To account for the two-stage sampling design, weighted multinomial logistic regression
models were used to model the transitional probabilities of participants diagnosed with
normal cognition at a particular evaluation transitioning into MCI, dementia or stay as
cognitively normal at the next follow-up. Weighted multinomial logistic regression models
were also used to model the transitional probabilities of participants diagnosed as MCI at a
particular evaluation reverting to normal cognition, stay as MCI, or progress to dementia.
The multinomial logistic models used transitional states as the outcome variables with age,
gender, years of education and performance groups from stage one cognitive assessment as
independent variables. The weights were the reciprocals of sampling probabilities for
clinical assessment at each evaluation.
The person-years method was used to estimate age and gender specific annual transitional
probabilities from normal cognition or MCI. For each individual in the study, we first
determined the observation time contributed to a given age and gender group. We then
summed individual observation times for a given age and gender group over all cohort
members so as to obtain the total number of person-years of observation in that category.
The total number of participants with a particular transition was estimated by summing
predicted probabilities of the particular transition from the weighted multinomial models
over all participants in the age and gender combination group. Since not all participants
received clinical evaluation at the second stage, weighted multinomial models combining
data from all evaluation waves and accounting for sampling selection were used to provide
estimated probabilities of participants diagnosed as normal cognition or MCI at each
evaluation wave. Both the estimated cases of transition and the person-years at risk were
further adjusted by these estimated probabilities for those not clinically evaluated in a
previous wave.
The transition rates for a specific age and gender group were derived as the total estimated
number of a particular transition divided by the total person-years at risk for the age and
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gender group. Since the transition rates were derived from complex models, we chose to use
a nonparametric method, the jackknife variance estimator, for the derivation of standard
errors of the rates. The jackknife variance estimator has been shown to be a consistent
variance estimator for data from complex sampling38 and is more stable than the bootstrap
estimator.39
Age-standardized overall transition rates were obtained by applying the estimated age and
gender specific rates to the age and gender distribution of African American residents in
Marion County (Indianapolis) observed in the 2000 census. The variance of the overall age-
standardized rate was calculated as a weighted mean of the variances of the age and gender
specific rates. Ninety-five percent confidence intervals for the transition rates were
constructed based on asymptotic normality of the estimates.
Results
In the baseline evaluation of the 1992 cohort, 65 participants were diagnosed with dementia
leaving 2147 participants free of dementia and eligible for continued follow-up evaluation.
In the baseline evaluation of the 2001 cohort, 57 participants were diagnosed with dementia
leaving 1835 participants eligible for continued follow-up evaluation. Thus a total of 3982
subjects were included in this analysis. The maximum follow-up time was 17.6 years for
participants in the 1992 cohort and 8.5 years for those in the 2001 cohort. Mean follow-up
time was 5.9 years (SD=5.2) for participants in the 1992 cohort and 4.4 years (SD=3.1) for
the 2001 cohort. Figure 1 provides a schematic flow of the longitudinal study and
information on loss to follow-up due to death, refusal and other reasons at each evaluation.
In Table 1, we present the baseline characteristics of study participants divided into three
groups: those diagnosed with incident dementia during follow-up, those diagnosed with
MCI at any time during the study, and those free of dementia or MCI during follow-up. In
both cohorts, age, years of education, history of smoking and baseline CSID scores were
significantly different among the three groups. In addition, the 2001 cohort also showed
significant difference in the proportions of female, cancer, stroke and depression among the
three groups while no significant differences on these proportions were seen in the 1992
cohort.
We present clinical outcomes during two consecutive evaluations in Table 2. Few
individuals transitioned from normal cognition to dementia between two consecutive
evaluations, but a substantial number of normal participants and those without clinical
assessments were diagnosed as MCI at the subsequent evaluation. Table 3 presents age and
gender specific annual transition rates from normal cognition to MCI, dementia or AD. For
both men and women, the transition rates from normal cognition to MCI, dementia or AD
increase with age. For participants in age groups 75–79 and 80–84, male participants had
significantly higher MCI incidence rates, i.e. transition rates from normal cognition to MCI,
than females based on the non-overlapping confidence intervals, while no significant gender
difference was found for the other age groups. For older participants (age ≥ 80), female
participants had significantly higher annual transition rates from normal cognition to
dementia than males. The overall standardized annual incidence for MCI is 5.6% (95% CI:
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4.6–6.6%), and the overall standardized annual transition rate from normal cognition to
dementia is 0.6% (95% CI: 0.6–0.7%).
Table 4 presents age and gender specific annual transition rates from MCI to normal
cognition, dementia or AD. For the reversion rates from MCI to normal, a decreasing trend
with age was seen where older participants were less likely to revert back to normal than
younger participants. Progression rates from MCI to dementia or AD, on the other hand,
increased with the increase of age. No gender difference was seen for any of the transitions
from MCI. The overall standardized annual reversion rate from MCI to normal cognition is
18.6% (95% CI: 16.7–20.4%). The overall standardized annual progression rate from MCI
to dementia is 5.9% (95% CI: 5.3–6.5%). Figure 1 is a graphical display of these transitional
rates.
Discussion
Previous studies on MCI incidence have used the traditional closed cohort approach by
following only individuals with normal cognition at baseline to observe new MCI cases.
Similarly, studies on MCI to dementia conversion were conducted by following only the
group of MCI individuals at baseline and observing their progression to dementia. Given the
transient nature of the MCI group, a closed cohort approach would not be able to
appropriately adjust for transitions between normal cognition and MCI during the follow-up
period. Our study uses a dynamic cohort approach to simultaneously estimate the transition
probabilities among normal cognition, MCI and dementia, thus allowing the modeling of
dynamic changes in cognitive status of all individuals in the cohort.
Among community-based and clinic based studies reporting incidence of MCI, annual
incidence rates of MCI varied greatly from 0.85% to 12.2%.3–5, 7–19 In Figure 3, we present
annual incidence rates of MCI reported in previous studies and our results. The discrepancy
in MCI incidence rates was largely attributed to differences in MCI definitions which
includes cognitive impairment no dementia (CIND), age-associated memory impairment
(AAMI), mild cognitive impairment (MCI), and amnestic MCI (aMCI) with aMCI being the
most restrictive. Difference in rates may also reflect differences in age ranges, sample sizes,
study populations, lengths of follow-up, and geographic regions. Among studies using
similar diagnostic criteria to ours, there is a closer agreement in incidence rate estimates.
Plassman et al reported annual CIND incidence of 6.04% 40 with an eight-year follow-up
and the Canadian Study of Health and Aging reported annual incidence rates of 4.58% and
5.68%, respectively, for two populations followed for five years,18–19 all in close agreement
with our overall annual incidence rate of 5.6%.
Progression rates from MCI to dementia have been reported much higher progression rates
in clinic-based cohorts than in community-based cohorts.20, 41 In community-based studies,
annual progression rates from MCI to dementia ranged from as low as 0.9% 42 to as high as
15.3%.43 It should be noted that the meta-analysis of twelve community-based MCI studies
reported a pooled annual progression rate from MCI to dementia to be 5.2% (95% CI: 2.9–
8.0%), which is very similar to the 5.9% annual progression rate found in this study, despite
of the wide variability in MCI dementia progression rates seen in these studies.20
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Several epidemiological studies have reported that 16% to 50% of individuals with MCI
reverted to normal cognition during various length of follow-up ranging from 3 to 10
years.2–5, 7 Since some studies did not provide annual rates, it is difficult to directly compare
our MCI reversion rates to these previous rates. Our analysis provides the longest follow-up
in studies reporting MCI reversion rates. In our cohort, about 18.6% of MCI individuals
reverted to normal cognition annually. However, the reversion rates decrease greatly with
the increase in age, and in the older age groups more MCI individuals progress to dementia
or AD than reverting to normal cognition.
Our results indicate a much higher transition rate to dementia from individuals with MCI
than those with normal cognition, providing support to the notion that MCI as a group is at
greater risk for dementia and should perhaps be targeted for early intervention to delay their
transition into dementia. However, our results also highlight a cautionary note that a
substantial proportion of individuals in the MCI group, especially those in the younger age
groups, are more likely to revert back to normal cognition. Further research identifying
predictive factors for progression or reversion in MCI individuals is needed to better define
sub-groups within MCI so that intervention could be delivered to those at the early stage of
dementia and unnecessary treatment could be avoided in those who would revert to normal
cognition.
Most previous studies either included only Caucasian participants or did not separately
report rate estimates by racial groups. We found no MCI incidence, progression or reversion
rates for African Americans in the literature other than a report of incidence estimates from
our study with a shorter follow-up.7 In spite of the higher prevalence rates of AD and
dementia in African Americans reported in some studies,21 our previous publications
reported AD and dementia incidence rates comparable to those found in Caucasian
populations.26 Our results are similar to those reported from large community-based studies
of Caucasians suggesting little or no difference in MCI incidence or progression rates
between African Americans and Caucasians. This conclusion however will need to be
verified by studies with sufficiently large samples of both African Americans and Caucasian
participants to rule out potential biases due to differences among studies.
Our study has the strength of a long follow-up period in a large dynamic cohort of elderly
African Americans. Identical diagnostic criteria were used throughout the entire study
period, ensuring diagnostic consistency. In addition, random sampling was used for the
selection of clinical assessment, thus permitting the use of weighted models to appropriately
adjust for the sampling schemes and for the use of predicted probability of transitions.44
Our study also has limitations. The study included only African American participants, thus
it is not known whether the rates reported here are generalizable to other elderly populations.
We present transition rate estimates for all MCI individuals instead of by various MCI
subtypes in order to preserve sufficient sample size for the modeling approach used in this
analysis. Since not all study participants received the extensive clinical assessment at the
second stage, our estimated transition rates may not be as accurate as if every participant had
received the extensive clinical assessment. Nevertheless, the two stage sampling design and
our model-based approach have been used in many epidemiologic studies to estimate both
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prevalence and incidence rates 25–26, 45 and have been shown to provide unbiased and
accurate estimates under various assumptions.44
Our rate estimates could also be affected by selection biases from participants’ refusal to
enroll in the study, in particular, the relatively high refusal rate in the 2001 cohort. Despite
differences in enrollment strategies, our previous analyses found no differences in
prevalence rates of dementia or AD between the 1992 cohort and the 2001 cohort.24 Our
decision to estimate transition rates using the combined cohorts provides large sample size
for stable rate estimates for age and gender subgroups. But selection bias based upon the
differential refusal rates cannot be entirely ruled out. Another source of potential selection
bias comes from refusals to the second stage clinical assessment. Although our smoothed
estimates provides unbiased rate estimates if refused participants differed in age, gender,
education or performance groups from those evaluated, potential bias may be introduced if
the two groups differed on other characteristics not controlled in the logistic models.
In summary, in this elderly African American population we found that MCI individuals
convert to dementia at a higher rate than individual with normal cognition. A substantial
number of MCI individuals in the younger age groups revert to normal cognition during
follow-up. Both MCI incidence rates and MCI to dementia progression rates increase with
age, while reversion rates from MCI to normal decrease with age. Future research is needed
to identify factors related to MCI progression and reversion.
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Figure 1.
Flow chart of the number of study participants evaluated during follow-up.
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Figure 2.
Age and gender specific annual transition rates and 95% confidence intervals. Red lines
represent estimated rates (solid lines) and confidence intervals (dotted lines) in females.
Blue lines represent estimated rates (solid lines) and confidence intervals (dotted lines) in
males.
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Figure 3.
Incidence rates for mild cognitive impairment (MCI) reported in the literature and in this
study (horizontal line). Blue dots represent incidence rates for amnestic MCI and red dots
represent rates for all types of MCI. The sizes of the dots are proportional to study sample
sizes.
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